Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26255466 | 0.95 | NAMPT (0.58) | NAMPTCYP2C9 | |
| SCHEMBL254886 | 0.85 | NAMPT (0.80) | NAMPTCYP2C9 | |
| SCHEMBL18569900 | 0.84 | NAMPT (0.60) | NAMPTCYP2C9 | |
| SCHEMBL20603245 | 0.80 | NAMPT (0.55) | NAMPTCYP2C9 | |
| SCHEMBL16220645 | 0.80 | NAMPT (0.61) | NAMPTCYP2C9 | |
| SCHEMBL12467978 | 0.79 | NAMPT (0.82) | NAMPTCYP2C9 | |
| SCHEMBL158934 | 0.79 | NAMPT (0.82) | NAMPTCYP2C9 | |
| SCHEMBL3492329 | 0.79 | MAOB (0.58) | NAMPTCYP2C9 | |
| SCHEMBL7516102 | 0.79 | MAOB (0.58) | NAMPTCYP2C9 | |
| SCHEMBL16220647 | 0.78 | NAMPT (0.65) | NAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007514744-A | — | — | 2007-06-07 | — | — | JP | claimed |
| EP-1697360-A1 | NOVEL CRYSTALLINE FORMS OF 2, 3 DIMETHYL-8- (2, 6-DIMETHYLBENZYLAMINO) -N-HYDROXYETHYL-IMIDAZO 1, 2-A PYRIDINE-6-CARBOXAMIDE MESYLATE SALT. | AstraZeneca AB (SE) | 2006-09-06 | — | — | EP | claimed |
| WO-2005058895-A1 | NOVEL CRYSTALLINE FORMS OF 2, 3 DIMETHYL-8- (2, 6-DIMETHYLBENZYLAMINO) -N-HYDROXYETHYL-IMIDAZO [1, 2-A] PYRIDINE-6-CARBOXAMIDE MESYLATE SALT. | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | claimed |
| EP-1697360-A1 | NOVEL CRYSTALLINE FORMS OF 2, 3 DIMETHYL-8- (2, 6-DIMETHYLBENZYLAMINO) -N-HYDROXYETHYL-IMIDAZO 1, 2-A PYRIDINE-6-CARBOXAMIDE MESYLATE SALT. | AstraZeneca AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058895-A1 | NOVEL CRYSTALLINE FORMS OF 2, 3 DIMETHYL-8- (2, 6-DIMETHYLBENZYLAMINO) -N-HYDROXYETHYL-IMIDAZO [1, 2-A] PYRIDINE-6-CARBOXAMIDE MESYLATE SALT. | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |